Literature DB >> 2932989

Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma.

P H Howarth, S R Durham, T H Lee, A B Kay, M K Church, S T Holgate.   

Abstract

The effect of pharmacologic agents on mast cell mediator release was investigated in vivo. Eight atopic asthmatic subjects with airways relatively unreactive to nonspecific stimuli (geometric mean PC20 methacholine, 4.0 mg/ml) underwent single-concentration allergen challenge before (control) or after inhaling albuterol 200 micrograms, cromolyn sodium 20 mg, or 0.9% sodium chloride placebo. Six of the same subjects also underwent allergen challenge after pretreatment with ipratropium bromide, 1 mg. Airway responses to pharmacologic agents and bronchial challenge were measured by change in both specific airway conductance (SGaw) and FEV1. Mast cell mediator release was monitored by serial change in plasma histamine and, in addition, serum neutrophil chemotactic factor (NCF) on the placebo, albuterol, and cromolyn sodium challenge days. Control and placebo allergen challenges were associated with repeatable mean maximal falls in SGaw (48.5 versus 49.6%) and FEV1 (25.7 versus 25.5%). The mean increments in plasma histamine were not significantly different on the control (0.17 to 0.44 ng/ml) or placebo challenge days (0.18 to 0.64 ng/ml), with maximal levels occurring 5 min after challenge. A sustained increase in NCF was identified on the placebo challenge day (155.0% above baseline). Pretreatment with albuterol abolished any significant bronchoconstriction, with mean maximal falls in SGaw and FEV1 after challenge of 7.5 and 1.4%, respectively. These changes in airway caliber were not associated with any significant increment in mean plasma histamine (0.17 to 0.22 ng/ml) or serum NCF (4.1% increase). Cromolyn sodium pretreatment, while attenuating the airway response, was still associated with significant falls in SGaw (22.7%) and FEV1 (7.3%) and increases in plasma histamine (0.18 to 0.27 ng/ml).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2932989     DOI: 10.1164/arrd.1985.132.5.986

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  37 in total

1.  Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs.

Authors:  A Ben-Jebria; D Chen; M L Eskew; R Vanbever; R Langer; D A Edwards
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

Review 2.  Leukocyte activation following IgE dependent mechanisms in bronchial asthma.

Authors:  S R Durham
Journal:  Clin Rev Allergy       Date:  1989

3.  Current issues with beta2-adrenoceptor agonists: historical background.

Authors:  Anne E Tattersfield
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 4.  Regulation of mast cells by beta-agonists.

Authors:  Peter Peachell
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

5.  Mechanism of adenosine-induced airways obstruction in allergic guinea pigs.

Authors:  Sandra Keir; Victoria Boswell-Smith; Domenico Spina; Clive Page
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

6.  Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs?

Authors:  M K Church
Journal:  Agents Actions       Date:  1986-06

7.  Bronchial biopsy evidence for leukocyte infiltration and upregulation of leukocyte-endothelial cell adhesion molecules 6 hours after local allergen challenge of sensitized asthmatic airways.

Authors:  S Montefort; C Gratziou; D Goulding; R Polosa; D O Haskard; P H Howarth; S T Holgate; M P Carroll
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

8.  Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung.

Authors:  P R Butchers; C J Vardey; M Johnson
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

Review 9.  Treatment of childhood asthma: how do the available options compare?

Authors:  David Coghlan; Colin Powell
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin.

Authors:  C J Whelan; M Johnson
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.